ArticleAnnals of surgical oncology2025
Sex-Based Differences in Medullary Thyroid Cancer Survival: A Matched Analysis of 4602 Patients.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhereas medullary thyroid cancer (MTC) is more common in female patients, studies have indicated that MTC is more aggressive in males. It is unknown whether sex-based differences in MTC outcomes are due to inherent tumor behavior or factors such as care characteristics.
methodsPatients with MTC stages I to IV were identified using the National Cancer Database (2004-2020). Male patients were matched one-to-one with females based on pathologic staging. Overall survival (OS) was estimated using the Kaplan-Meier method. A Cox proportional hazards model was used to estimate the association of biologic sex with OS.
resultsThe study matched 4062 patients (2031 females and 2031 males). The median age was 55 years (interquartile range, 43-66 years). Age, race, comorbidity score, and care characteristics such as time to diagnosis and surgery type did not differ by sex (all p > 0.05). Pathologic stage was primarily stage IVA (35.5%), followed by stages I (24.7%) and III (18.9%). The unadjusted 10-year OS for the female patients was 81.1% (95% confidence interval [CI], 78.7-83.2%) versus 69.6% (95% CI 66.8-72.3%) for the male patients (p < 0.001, log-rank). Survival for the male patients with stages II, III, and IVA disease was significantly worse (all p < 0.05). After multivariable adjustment, the male patients showed an 81% higher mortality risk than the female patients (hazard ratio [HR], 1.81, 95% CI 1.50-2.20; p < 0.001).
conclusionsDespite patient-matching and adjustment for several factors, the male patients with MTC demonstrate worse survival than the matched female patients. These findings indicate that MTC behavior differs by sex.
Indexed as
Identifiers
40839143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.